Welcome to our dedicated page for STELLA DIAGNOSTICS news (Ticker: SLDX), a resource for investors and traders seeking the latest updates and insights on STELLA DIAGNOSTICS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect STELLA DIAGNOSTICS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of STELLA DIAGNOSTICS's position in the market.
Stella Diagnostics, Inc. (SLDX) announced that its research on the STLA101 panel of biomarkers will be presented at Digestive Disease Week 2022 on May 21, 2022. This panel can distinguish between intramucosal and invasive esophageal adenocarcinoma, addressing the challenges in identifying cancer stages. The session will highlight the dual utility of the STLA101 markers, which can significantly aid in the precise diagnosis of esophageal cancer. Esophageal adenocarcinoma cases have surged by 700% in 40 years, underscoring the need for effective diagnostic solutions.
Stella Diagnostics (OTC: SLDX) announced significant leadership changes aimed at enhancing its business strategy for precancerous and cancerous esophageal diseases. Dr. Joe Abdo will become Chief Scientific Officer, while David Seaburg, previously a Board member, has been appointed Chief Executive Officer. This transition is part of a succession plan to leverage internal expertise for future development. Seaburg brings extensive experience from Wall Street, while Abdo has a strong background in molecular oncology research. The company aims to commercialize innovative diagnostic tests for early disease identification.
Stella Diagnostics, Inc. (OTC: SLDX) announced a data presentation at the American Association for Cancer Research (AACR) Annual Meeting, April 8-13, 2022. Dr. Christopher Hartley from the Mayo Clinic will present on the STLA101 panel, which detects cancer hallmarks in Barrett's esophagus patients. The AACR conference, with over 49,000 members, is a significant event for clinical research in oncology. This presentation is crucial, given the rising incidence of esophageal adenocarcinoma, which has increased by 700% over four decades. The company's diagnostic assay aims to improve early detection and patient management.
Stella Diagnostics (OTC: SLDX) has been named a semi-finalist for the SAGES Shark Tank 2022 competition and will present clinical data on its STLA101 assay for Barrett's esophagus at the SAGES Annual Meeting in Denver from March 16-19, 2022. The presentation will be led by Dr. Sumeet K. Mittal and co-presented by Dr. Christopher Hartley from the Mayo Clinic. Esophageal adenocarcinoma's incidence has surged by 700% over four decades, highlighting the need for early detection methods like those offered by Stella.
Stella Diagnostics announced its STLA101 mass spec proteomic assay (BEsmart™) won the “Best Clinical Proteomics Solution of the Year” at the 2021 BioTech Breakthrough Awards. The awards program received over 1,200 nominations globally. Dr. Joe Abdo, CEO, expressed gratitude for the recognition, emphasizing the assay's clinical utility for early diagnosis of Barrett’s esophagus and esophageal cancer, a rapidly growing health issue in the U.S. Stella Diagnostics aims to enhance patient management strategies for over 60 million individuals suffering from severe esophageal diseases.
AUSTIN, Texas, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Stella Diagnostics (OTC Pink: SLDX) announces advancements in precancerous screening for esophageal cancer. CEO Dr. Joe Abdo discusses their innovative diagnostic tools aimed at identifying risks associated with Barrett's esophagus, a precursor to esophageal cancer. With over 60 million Americans affected by GERD, early detection is critical. Stella's technology enhances current screening methods by providing robust molecular data, potentially allowing for earlier intervention and improved patient outcomes.
Stella Diagnostics, Inc. (OTC Markets:SLDX) contributed to a peer-reviewed article in the Journal of Gastrointestinal Oncology discussing the challenges and advances in diagnosing Barrett's esophagus-related cancer. The article emphasizes significant progress in molecular diagnostics but notes a lack of clinical adoption and approved therapies that ensure durable responses. Dr. Joe Abdo, CEO, highlights the need for improved diagnostic protocols to support clinical decision-making. For access to the full article, visit the journal's website.
Stella Diagnostics, Inc. (OTC PINK:JMDP) has officially changed its corporate name from JMP Properties, Inc. to Stella Diagnostics, Inc., effective April 16, 2021. Alongside the name change, the company’s common stock will now trade under the new ticker symbol SLDX. This rebranding aligns with the company's mission to enhance patient management strategies for over 67 million individuals suffering from severe esophageal diseases. CEO Dr. Joe Abdo emphasizes that the name and ticker change are crucial for strengthening their brand and mission.
FAQ
What is the market cap of STELLA DIAGNOSTICS (SLDX)?
